Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Vertex Pharmaceuticals ( VRTX) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Vertex Pharmaceuticals as such a stock due to the following factors:

VRTX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $149.9 million.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Currently there are 8 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 10 rate it a hold.

The average volume for Vertex Pharmaceuticals has been 1.4 million shares per day over the past 30 days. Vertex has a market cap of $32.1 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.99 and a short float of 1.7% with 3.59 days to cover. Shares are up 10.8% year-to-date as of the close of trading on Wednesday.